Compare ARK Genomic Revolution ETF (ARKG) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs McCormick & Company, Incorporated — how do they compare? ARK Genomic Revolution ETF trades at $41.29, while McCormick & Company, Incorporated trades at $53.57 (market cap $14.08B). The key difference: McCormick & Company, Incorporated pays a 3.66% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, McCormick & Company, Incorporated nearer its low. Which is the better fit depends on your goals.
| ARKG | MKC | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $72.81 |
52-Week Low | $23.09 | $45.60 |
Market Cap | — | $14.08B |
Enterprise Value | — | $18.68B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
McCormick (MKC) trades at $52.45, up 1.77% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 21.91% net income margin and 25.7% ROE, supported by a transformative $45 billion Unilever Foods deal announced in July 2026. Valuation appears attractive with a P/E of 8.73, below industry averages, while cash flow trends indicate robust operational performance.
The outlook is mixed; analyst consensus targets $59.67 (14% upside) with a 'Hold' bias, but weak consumer volume growth and integration risks from the Unilever acquisition pose challenges. The stock offers a near 4% dividend yield, providing income support, yet execution on cost savings and volume recovery remains critical for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
